Abeprazan hydrochloride
Modify Date: 2024-01-15 10:48:26
Abeprazan hydrochloride structure
|
Common Name | Abeprazan hydrochloride | ||
|---|---|---|---|---|
| CAS Number | 1902954-87-3 | Molecular Weight | 446.87 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C19H18ClF3N2O3S | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of Abeprazan hydrochlorideAbeprazan hydrochloride (DWP14012 hydrochloride) is a potassium-competitive acid blocker. Abeprazan hydrochloride inhibits H+, K+- ATPase by reversible potassium-competitive ionic binding with no acid activation required. Abeprazan hydrochloride is developed as a potential alternative to proton pump inhibitor for the treatment of acid-related diseases[1]. |
| Name | Abeprazan hydrochloride |
|---|
| Description | Abeprazan hydrochloride (DWP14012 hydrochloride) is a potassium-competitive acid blocker. Abeprazan hydrochloride inhibits H+, K+- ATPase by reversible potassium-competitive ionic binding with no acid activation required. Abeprazan hydrochloride is developed as a potential alternative to proton pump inhibitor for the treatment of acid-related diseases[1]. |
|---|---|
| Related Catalog | |
| In Vitro | The mechanism of action of Abeprazan hydrochloride is reversibly binding to H+, K+‐ATPase, and, unlike that of PPIs, does not require acidic environment for drug activation[1]. |
| In Vivo | Abeprazan hydrochloride (DWP14012 hydrochloride) inhibits acid secretion in a dose-dependent manner and the inhibition of gastric acid secretion is equal to or greater than that of vonoprazan, a previously approved P-CAB, in various in vivo studies using pylorus-ligated rats, lumen-perfused rat models and heidenhain pouch dog models[1]. |
| References |
| Molecular Formula | C19H18ClF3N2O3S |
|---|---|
| Molecular Weight | 446.87 |